标签： 苏州桑拿夜生活

　　[Car History] The brand’s flagship model CROWN was born in 1955 and has undergone more than half of its evolution. As one of the earliest imported luxury cars to enter the Chinese market, the Crown has a high degree of recognition in people’s hearts. On December 25, 2012, the 14th generation of the Crown was officially released in Japan. The newly released Crown has been further improved in all aspects. At the same time as the launch of the new Crown, we will also review the development of the Crown car series.

Notes: Since the Crown car series has 14 generations of models and is longer, this article will be divided into two chapters for everyone to introduce, the first one introduces the evolution history of the first to seventh generation models.

◆ Toyota CrownOriginAnd its birth background (early 1950s)
　　Built specifically for the business market

　　In the early 1950s, in order to better meet the growing demand for corporate vehicles in Japan, Toyota began to develop the Crown sedan for business people, preparing to replace the previous RH model. However, Toyota was not sure whether the new design of the Crown would be acceptable to the market, so it also launched a slightly more conservative design of the Master model, mainly for the taxi market. However, due to the popularity of the Crown, Toyota discontinued the Master and changed its factory to produce the Crown.

　　The RH, also known as the Super, was the fourth generation of Toyota’s first SA line-up after World War II, when the more competitive Crown replaced the RH as the mainstay in 1955.

Toyota’s first-generation Crown (1955-1962)
　　Features: Compact/with open doors

　　In January 1955, the first generation of Toyota’s self-produced Crown sedan was officially launched, and the first Crown was personally driven off the production line by President Hideji Toyota. The crown at that time had typical characteristics of the times in terms of styling design. The first generation of the crown used a ship-shaped body, the front of the car had two independent cylindrical headlights, the prominent cover was designed with prisms, the grille was designed with two layers inside and outside, and the lower bumper was also designed to be more prominent.

　　The most distinctive design on the sides of the car is the folio of the front and rear doors to make it easier for passengers to get on and off. The same design was used on Toyota’s first model, the AA. The straight line at the rear of the body extends to the rear of the car, and the luggage compartment cover is designed to be streamlined.

　　In today’s standards, Toyota’s first-generation crown is just one, its length, width and height are: 4285mm × 1679mm × 1524mm, 2530mm, and its body size is close to today’s. The curb weight of the first-generation crown is 1152kg.

　　The first generation of Toyota Crown was exported overseas, so there are both left and right rudder forms. The design of the car is very simple, the shift lever is located on the side of the steering column, and the central control part is made of metal. Except for simple instrument display and light control, there are only a few functional configurations. The front and rear seats of the first generation of Crown are all integrated headless design, which can seat up to six people.

　　In the power part, the Crown was originally equipped with a Toyota R series 4-cylinder engine with a displacement of 1.5L and a maximum of 49 horsepower. It transmitted engine power to the rear wheels at 3 speeds. In the chassis part, the structure of the first-generation Crown was an independent front suspension and a non-independent rear suspension.

　　In December 1955, Toyota introduced the Crown Deluxe Edition, which turned the left and right windshields into one piece, and upgraded the radio and warm air to standard configuration. In October 1958, the Crown ushered in the first facelift, and the changes in the new car were mainly reflected in the appearance and power. The front face was redesigned, the headlights were added with a protective cover, the grille style was more holistic, the trim strips on the side of the body were extended to the rear, the trunk cover became angular, and the area of the taillights was also increased. In terms of power, the facelift model followed the R series 1.5L engine, but the power output of the standard version was increased to 61 horsepower, and the power output of the deluxe version was increased to 63 horsepower.

　　In October 1959, Toyota first launched the equipped Crown model, which was also the first diesel sedan in Japan. It was equipped with the Toyota C series engine with a displacement of 1.5L and a maximum power of only 40 horsepower. In October 1960, the Crown ushered in a facelift again. The new car was equipped with a new 1.9L 3R engine, and the transmission part could choose 2 speeds in addition to a 3-speed manual transmission. The 1.9L power version was originally only equipped with the Crown Deluxe Edition (maximum power 96 horsepower). In April 1961, the Crown Standard Edition was also equipped with a 1.9L engine (maximum power 86 horsepower).

　　In terms of special editions, the first-generation Crown was introduced as a taxi version in March 1959, in addition to two commercial vehicle editions: and.

　　From 1957 to 1960, the first-generation Crown became the first Japanese car to be exported to the United States, but it sold only 287 units. To promote the reliability of the Crown, Toyota held long-distance endurance races from Los Angeles to New York. Unfortunately, it did not have a positive effect because the Crown withdrew from the race shortly after the start of the race.

　　The Crown was "unsuitable" in the United States, because the car was only equipped with a small 1.5L engine in the face of the characteristics of Japanese road conditions at the time (mud, low speed, unpaved). The embarrassment of insufficient power caused the Crown to be criticized in the United States. Even after being upgraded to a more powerful engine, sales still did not improve.

Xiao Ai uses a female voice by default, but if you need it, you can also set Xiao Ai’s voice, change the tone, and add your own voice! The following editor brings you a tutorial on Xiao Ai’s customized voice. If you don’t know how to get it, let’s take a look together!

1. Activate the mobile phone Xiao Ai classmate said " Customized sound experience ", awaiting approval of the application;

2. Open the settings in the mobile phone after passing the application, and click Xiao Ai;

3. Click "on the Xiao Ai classmate interface. Xiao Ai Lab ";

4. Click " tone settings ";

5. Enter the tone settings interface and click " Add my voice ", just make the audio according to the prompts.

The above is the Xiao Ai brought by the editor. How to set your own voice? Customize the sound tutorial. For more related information tutorials, please pay attention to PConline.

1905 movie network news On September 18, the film released the promotional song "Like a Rainbow" MV. While showing the two young singers UNINE Xia Hanyu and Chen Xuening singing affectionately, the MV also exposed more thrilling new scenes in the film in which the mountaineers played by Wu Jing, Zhang Ziyi, Zhang Yi, Jing Boran, Hu Ge, etc. joined forces to fight storms and avalanches during the process of reaching the summit of Mount Everest, and erected "Chinese ladders". At the end of Wu Jing’s promise of "what I promised you, I will definitely be able to do it" is also very touching. The singers UNINE Xia Hanyu and Chen Xuening also expressed that they are very honored to write the "musical afterthought" for the film through their singing, hoping to inspire more young people to inherit the spirit of their predecessors and pay tribute to the immortal glory of heroes. The film will be released on National Day on September 30 and is now available for pre-sale nationwide.

Climbing Alliance Charge Encounters Danger, Wu Jing’s promise to climb the summit touches people’s hearts

Previously, the movie "Climber" promotional song "Ruhong" was launched, and on the day of release, it reached the first place in the music peak popularity ranking of an authoritative platform, as well as the first place in the Weekly Ranking of the same period of music peak popularity ranking. At the same time, it also received many hot comments from netizens: "UNINE Xia Hanyu and Chen Xuening’s two young singers’ affectionate interpretation of" Ruhong "makes people feel the power of emotion, and sings the friendship, love and family and national feelings that support the climbers to move forward bravely and climb Mount Everest." Another fan said: "’Like a Rainbow’ shows us not only the love of making a rainbow, but also the spirit of the climbers who are not afraid of difficulties and face difficulties is the pride of the people. It also makes me look forward to the story of the climbers in the film’measuring the height of the motherland with their footsteps’."

In the "Rainbow" MV released this time, it is also exposed that the mountaineers played by Wu Jing, Zhang Ziyi, Zhang Yi, Jing Boran, Hu Ge, etc. in the film, join hands to fight against storms and avalanches during the process of reaching the summit of Mount Everest, and jointly erect a new picture of "China Ladder". The promise of Wu Jing at the end, "What I promise you, I can definitely do it", is also extremely touching and tearful. Although the mountaineers in the film have different experiences and pasts, they gather together for the same goal of climbing Mount Everest and shoulder the national responsibility and mission of climbing Mount Everest together. The thrilling and shocking film images in the MV, together with the touching singing and lyrics of "Like a Rainbow", also make people feel as if they are in the story of the film, and feel the determination and belief of the climbing alliance to climb Mount Everest side by side.

UNINE Xia Hanyu Chen Xuening expresses her musical experience and pays tribute to every climber

For the collaboration to sing the promotional song "Rainbow" of the movie "Climber", UNINE Xia Hanyu and Chen Xuening, two excellent young singers, also expressed their great honor, and admitted that they hoped to convey the climbing spirit of the climbers in the film in the form of "music after reading" through their singing, and inspire more young people to inherit the spirit of their predecessors and continue to move forward bravely.

For the first collaboration between the two, UNINE Xia Hanyu said that this "Rainbow" is a "musical afterthought" they dedicated to the movie "Climber", and it is also a "dialogue" between them and the climbing heroes: "Even if there is a storm and blizzard on the climbing road, we will fearlessly go all out for our dreams and pay tribute to the climbing heroes." Chen Xuening also said with emotion: "I specially learned about the deeds of the climbing heroes before, and I admire them from the bottom of my heart." Rainbow "is like a soft bond that connects the present with the past, resulting in the glory of the immortal heroes."

The film "The Climber" is produced by Tsui Hark and Zeng Peishan, written and directed by Li Rengang, written by Alai, written by Wu Jing, Zhang Ziyi, Zhang Yi, Jing Boran, Hu Ge, Wang Jingchun, He Lin, Chen Long, Liu Xiaofeng, Quni Tsering, Lavan Rob, and Dobj. Jackie Chan starred in a friendship. The film will be released on the National Day file on September 30, and is now available for pre-sale nationwide.

Recently, the one-stop car information, trading and service platform Dcar released the latest weekly sales list of China’s new energy market (10.16-10.22). The data shows that the much-watched Wenjie M7 sold a total of 2,461 units last week, only 12 units short of the weekly sales of the ideal L8, which makes the new car-making force "First Brother" feel pressure. However, the ideal under pressure did not drop the chain. Last week’s sales were still "far ahead", reaching a weekly sales volume of 9,100 units, which is exactly the sum of Xiaopeng and NIO. There is little suspense that the sales volume in October broke 40,000.

On September 12, the new Wenjie M7 jointly launched by Huawei and Sailis was officially released. After the car was launched, it set a record of "50,000 units in 25 days and 7,000 units in a single day". The weekly sales data of new energy vehicles released by Dcar also confirmed the popularity of this model. The data shows that the sales of Wenjie M7 reached 2,461 units last week, and the gap between the ideal L8, which is the main model of the large SUV market in the 250,000 yuan to 350,000 yuan, is only 12 units. With the current popularity of Wenjie M7, next week’s sales will exceed the ideal L8 or be a high probability event.

The explosion of the new Wenjie M7 has brought some pressure to the ideal. An ideal salesperson said that "many consumers will compare us with the Wenjie". However, as the "first brother" of the current new car-making force, the ideal sales are still "far ahead". Sales data from Dcar shows that last week’s ideal weekly sales were 9,100 units, which is exactly the sum of Xiaopeng and NIO’s weekly sales. In terms of models, last week’s ideal L7 sales were 3,400 units, L9 3,200 units, and L8 2,500 units, all ranking among the top ten weekly sales of new energy SUVs.

It is understood that Li Auto delivered a total of 36,000 vehicles in September. On the evening of October 8, Li Xiang, the founder of Li Auto, said on Weibo that the company will break through the monthly delivery volume of 40,000 vehicles in the fourth quarter. Judging from the performance of the first three weeks of October, the ideal October sales broke 40,000 basic board DingTalk.

In addition, from last week’s brand sales list of new energy vehicles, Xiaopeng replaced Geely and entered the top ten. At the same time, Xiaopeng G6 also ranked among the top ten weekly sales of new energy SUVs by relying on smart driving attributes, showing a good recovery momentum.

It is worth mentioning that from the data released by Dcar, the penetration rate of new energy vehicles in our country has reached 41.55% last week, and the month-on-month (39.16%) continues to increase. In terms of months, the domestic retail penetration rate of new energy vehicles in September was 36.9%.

Upstream news, Ma Liang

Text/Lu Shiming

Executives "talk to each other" at the car launch conference, or it will become a normal state of the industry.

Not long ago, Huawei held the HarmonyOS Ecological Spring Communication Meeting and released a number of new products. At the press conference, Yu Chengdong, managing director of Huawei, BG CEO, chairman of BU, Huawei’s smart car solution, and Yin Tongyue, chairman of Chery Automobile, released the first smart car, Zhijie S7, for the second time.

It is understood that the newly released Zhijie S7 has launched five models, among which S7 Ultra has been added as a high-end model. The official guide price is 249,800 to 349,800 yuan, and the price range is consistent with the old model.

Standing on the level of public opinion, the public doesn’t seem to be interested in the product itself, but what really makes people relish is Yu Chengdong’s series of remarks on "targeting" Xiaomi.

From the mobile phone stand to intelligent driving, Yu Chengdong’s "insinuation" of Xiaomi is familiar, just like the "routine" of the two companies at the mobile phone conference for many years.

However, the trend of executives of the two companies "talking to each other" from a distance has blown to a new battlefield this time, and the "grudges and enmities" between the two companies over the years will also stage a new story in the automobile market.

Yu Chengdong has never been soft on "friends". In this release, Yu Chengdong made many statements all the time, which can be said to be "tit for tat" with Xiaomi.

At the previous Xiaomi SU7 conference, Lei Jun once said: "I found that all the car manufacturers did not consider how to install the mobile phone bracket, and none of them worked well. We must make the best mobile phone bracket!"

At the S7 conference of Zhijie, Yu Chengdong said in a meaningful way: "I really don’t understand why many cars use mobile phone stands. Later, I understood that their car navigation performance is not good! We will let the mobile phone application get on the bus in full, and the powerful heart does not need a mobile phone bracket! "

In addition, Yu Chengdong also intentionally emphasized that the utilization rate of car navigation in HarmonyOS is as high as 99%, while the utilization rate of other car navigation is only 31%, and the gap is "very large".

Regarding Yu Chengdong’s remarks, Lei Jun issued a document in Weibo, saying: "At their press conference, General Manager Huawei ridiculed the design of our original mobile phone bracket for Xiaomi SU7." At the same time, Lei Jun also asked questions and initiated a vote: Do you support the original mobile phone bracket in the car? Why do you think we made the original mobile phone stand?

Up to now, 271,000 people have voted for this activity, of which 231,000 support the original mobile phone stand of Xiaomi SU7 and 40,000 do not. Zinc Finance noticed that the highest praise message in the comment area of the event was: "I can do without it, but you can’t do without it."

In addition to the episode of mobile phone stand, Yu Chengdong also made a targeted "insinuation" on intelligent driving.

It is reported that Lei Jun once said: "The whole industry is in the city of NOA. We started user testing in April, officially opened ten cities in May, and opened nationwide in August!" At the press conference, Yu Chengdong said: "Huawei Smart Drive is a spot, not a futures, and it is the best spot!" In this regard, Lei Jun did not send a response.

At the press conference, we conducted parameter benchmarking and technical comparison, or emphasized the strength of functions, and then the senior management published a document on Weibo to "communicate with each other" from a distance. This marketing technique and rhythm has become commonplace in the mobile phone circle, especially Huawei and Xiaomi, who have used this routine perfectly.

However, this has become a "new thing" in the automobile circle. After all, no car company has conducted such a "blatant" benchmarking before, and there has been no precedent for executives to speak out about competitors’ weaknesses at the press conference.

Obviously, with the competitiveness of Huawei and Xiaomi in the automobile market becoming more and more prominent, the two companies that have been "loving each other and killing each other" for many years have reached the time of "short-term intersection", but this time the battlefield has changed from mobile phones to cars.

In fact, the relationship between Huawei and Xiaomi in the early days was not "tense" at all, and even very "harmonious".

In 2012, Yu Chengdong sent Weibo that he needed to learn Internet marketing from Lei Jun, and Lei Jun also responded that Huawei has always been an example for Xiaomi to learn. At that time, the relationship between the two families was very harmonious.

In 2013, Xiaomi gradually gained momentum and launched Redmi, and Huawei also announced its glory independence.

In terms of brand positioning, Redmi, like Glory, focuses on products with a thousand yuan level. Including the product level, Glory 3C, the first mobile phone after glory independence, is very similar in appearance and configuration to Redmi. Later, sales proved that the two companies’ choices were undoubtedly correct. In 2014, the shipments of Glory and Redmi rose sharply, which brought more revenue to the parent company.

Even if they all made achievements, they all became the best in the market. At that time, the atmosphere between Xiaomi and Huawei was still very relaxed.

When the time came to 2015, Huawei began to make full efforts in the mid-to-high-end market, and achieved outstanding results, and the Mate series emerged. However, in the same year, Xiaomi, due to the insufficient supply of Xiaolong processors, led to a crisis in brand reputation and sales began to decline.

On the other side of Xiaomi’s constant problems, Glory seized this opportunity, eating away a lot of market share originally belonging to Xiaomi and Redmi, and helped Huawei win the first sales volume that year.

There is no doubt that 2015 is a watershed in the relationship between the two companies, laying the groundwork for the future "mutual tearing" between the two companies.

Only a few years later, Huawei Xiaomi began real competition, and the executives of the two companies frequently exchanged ideas at their respective product launches.

For example, in May 2018, HONOR officially announced that it will release Glory play on June 6, which will launch Huawei’s "very scary technology." Xiaomi immediately said that "Xiaomi 8 has many very scary technologies". In this regard, Huawei directly responded that it has a lot of technology. "Do you want to learn? It’s very difficult, so you should study hard. "

By the end of 2019, Xiaomi and Glory started a war of words for a week, starting with Xiaomi’s public relations Pan Da’s announcement that Weibo publicly questioned the existence of false propaganda on the glory smart screen.

In the next few years, such incidents were frequently staged. Even in the last year or two, the "DISS Friends" session at the two press conferences was never absent.

However, from a historical perspective, the reason for the "frequent tearing" between the two companies is also inseparable from the changes in the market environment.

In the years when the two companies were "in love", Samsung and Apple occupied most of the market share. At that time, domestic mobile phones needed to unite and reduce internal friction because of insufficient technical strength. But by 18 years or so, Samsung Apple has begun to decline, while the domestic mobile phone under the rapid development is rising step by step.

Without the threat of foreign enemies, domestic mobile phone manufacturers have also started a new round of competition, and the story of Huawei and Xiaomi "killing each other" has begun.

In fact, in the fact that the entire mobile phone market is gradually sluggish, the "gunpowder smell" of the two companies in the past two years is far less strong than before. But who would have thought that as both companies entered the new energy vehicle market, those familiar "old plots" turned back.

In 2021, after Huawei officially started its automobile business, it always claimed that it would not build cars, but only help car companies build good cars.

So far, Huawei has really not violated this creed, but with the increasing "Chinese content" of the entire automobile circle, consumers have been unable to tell who is the "protagonist".

Up to now, Huawei has reached cooperation with many domestic car companies, such as "Wen Jie" with Selis, Aouita with Chang ‘an, Zhijie with Chery, Polar Fox with BAIC and so on.

Although there are many cooperations, Huawei’s cooperative brands are only "out of bounds", and others are not excellent. As the first smart car that it cooperates with Chery, Huawei’s expectation for the intelligent S7 is obviously higher than other brands. Not only is it equipped with Huawei’s best autonomous driving technology, but it has also gained an unprecedented "momentum" from Huawei.

Unfortunately, judging from the current results, the performance of the intellectual community is very unsatisfactory.

Zhijie S7 has been on the market for nearly five months, and its sales in these five months have failed to exceed 1,000 vehicles. Specifically, there were 115 and 784 vehicles in November and December last year, and 604 and 794 vehicles in January and February this year, respectively.

In the same price segment, on the other hand, Xiaomi SU7 stole the limelight after listing, and the heat continued to rise, and the sales volume was even more popular.

According to public data, Xiaomi Automobile delivered a total of 1,093 vehicles in the 14th week of 2024, ranking 9th among new energy automobile brands. In addition, in the brand sales ranking of the pure electric vehicle market of more than 200,000, Xiaomi Auto also successfully entered the list, ranking fifth with sales of 1.1 thousand vehicles, surpassing Zhijie and Xpeng Motors.

It is worth noting that the delivery of Xiaomi Auto started on April 3rd, and the 4th to 6th falls on Tomb-Sweeping Day holiday, so this data can not fully reflect the actual delivery potential of Xiaomi SU7.

The sales volume of Zhijie S7 can’t exceed 1,000 in five months, and the sales volume of Xiaomi SU7 will exceed 1,000 in the listing week.

Under such a "gap", Huawei can’t turn a blind eye. It must readjust its propaganda caliber and regard Xiaomi as its core competitor. This is also the reason why Huawei wants to "second" release the intelligent S7.

Huawei should re-emphasize the technical gap between Zhijie S7 and Xiaomi SU7, so as to gain more consumers’ recognition and increase sales.

After 2018, the "mutual tearing" between the two companies can be seen as a microcosm of the marketing war of mobile phone brands. Now, this process will be repeated in the automobile market.

So, who will be the ultimate "winner"? This question is not important. It is important to hope that Huawei and Xiaomi can benefit consumers with better technology under this kind of competition, so that the whole new energy automobile industry can reach a higher level.

Special statement: this article is authorized by the cooperative media to reprint the DoNews column, and the copyright of the article belongs to the original author and original source. The article is the author’s personal opinion and does not represent the position of DoNews column. Please contact the original author and original source for authorization. (Please contact idonews@donews.com if you have any questions.)

　　Yangcheng Evening News reporter Chen Zeyun Intern Zhang Song

　　The curtain of centralized collection of Chinese patent medicines is being opened. On September 14th, Guangdong Pharmaceutical Trading Center issued the Procurement Document with Quantity of 58 Pharmaceutical Groups such as Guangdong Alliance Qingkailing (Draft for Comment). The alliance regions participating in this centralized procurement include Guangdong, Shanxi, Henan, Hainan, Ningxia, Qinghai and Xinjiang, and the selected drugs in the centralized procurement of proprietary Chinese medicines in the seven provinces and regions are all the dosage forms and specifications of 58 generic drugs with large consumption and high purchase amount in the basic medical insurance catalogue.

　　The reporter of Yangcheng Evening News found that the 58 drugs collected by Guangdong Alliance are all proprietary Chinese medicines, among which 36 are exclusive varieties, such as Xiyanping, Lianhua Qingwen and Xiaoer Chiqiao Qingre, which have sold over 100 million yuan. There are also many commonly used drugs such as Qingkailing, antiviral oral liquid and orange phlegm cough. This also means that after chemical drugs, the "price-cutting boots" hanging on the head of Chinese patent medicines will finally fall.

　　58 "high price and large quantity" Chinese patent medicines were included in Guangdong centralized procurement.

　　According to the "Draft for Comment", the range of varieties purchased by the pharmaceutical group this time is all the dosage forms and specifications of 58 generic drugs with large consumption and high purchase amount in the basic medical insurance drug list. The main participants in the procurement are all public medical institutions in the alliance area, and medical institutions and designated pharmacies designated by medical insurance can participate voluntarily.

　　The centralized procurement of Chinese patent medicines led by Guangdong has made detailed requirements for dosage forms, quotation requirements and successful selection. The quotation of enterprises must be based on "daily average treatment expenses". On the basis of effective declared price, the lower the price, the easier it is to win the bid.

　　According to the "Draft for Comment", 58 kinds of Chinese patent medicines with high price and large quantity, including 36 exclusive varieties such as Aidi, Shenkang and Lianhua Qingwen, cover many popular Chinese patent medicines in the market. According to the data of Minenet, many drugs such as Suhuang Zhike Capsule, Xiyanping Injection, Bering Capsule, Lanqin Oral Liquid, etc., which are included in the centralized procurement alliance, will all exceed 100 million yuan in terminal sales in public hospitals in key cities in 2020.

　　Actively explore the centralized collection of Chinese patent medicines in many places

　　Under the normalization of centralized procurement, the centralized procurement of generic drugs and medical devices has gone through many rounds, and promoting the centralized procurement reform of Chinese patent medicines has become the key direction of the next medical reform. It has become a trend that the pace of centralized procurement extends from generic drugs to proprietary Chinese medicines. On August 9th, the website of the National Medical Insurance Bureau clearly revealed in the public reply "Suggestions on Accelerating the Centralized Procurement of Chinese Medicine and Formula Granules" that the next step, the Medical Insurance Bureau will, together with relevant departments, improve the quality evaluation standards of Chinese patent medicines and formula granules, adhere to quality priority, take clinical demand as the guide, and start with high-priced and large-quantity varieties to scientifically and steadily promote the centralized procurement reform of Chinese patent medicines and formula granules.

　　"At present, Chinese patent medicines have not yet risen to the level of national collection, or the provinces are taking the lead in trying." Shi Lichen, founder of Dingchen Consulting, told the Yangcheng Evening News reporter that the rapid progress of generic drug collection was due to the previous implementation of a consistency evaluation system, which allowed all generic drugs participating in the collection to compete in the market under the premise of unified specifications and unified efficacy. The difficulty of centralized collection of Chinese patent medicines stems from the fact that the origin, processing technology and dosage forms of different Chinese patent medicines are not uniform, which also leads to different curative effects of the same medicine.

　　The reporter found out that before Guangdong, Qinghai Province, Jinhua, Zhejiang Province, Puyang, Henan Province and other places had carried out centralized exploration for some varieties of Chinese patent medicines with large demand and high amount. Among them, in November 2019, Jinhua City, Zhejiang Province included 180 Chinese patent medicines in the procurement with quantity. In May 2020, the catalogue of procurement with quantity published by Qinghai Province also included traditional Chinese medicine injections such as Xuesaitong, Xueshuantong, Tanreqing and Xiyanping.

　　How much to reduce the price depends on the centralized purchasing strategy

　　"The purpose of centralized collection of Chinese patent medicines and centralized collection of chemical medicines is the same, both of which are to promote drug price reduction. However, because most of the products included in centralized mining are exclusive varieties, how much the price reduction can be reduced depends on the centralized mining strategies of various provinces and cities. " Shi Lichen said.

　　How much can the price reduction of centralized collection of Chinese patent medicines be reduced? Taking the previous regional centralized procurement as an example, in the publicity list of the second batch of enterprises to be selected for purchasing drugs with quantity published by Jinhua City, Yunnan Baiyao selected compound Danshen tablets (0.3g/ tablet) at a price of 0.18 yuan, and Zhejiang Kangenbei selected ginkgo leaves at a price of 0.71 yuan/tablet (containing 19.2mg of total flavonol glycosides and 4.8mg of terpenoid lactones). The reporter found that the price reduction of the above drugs is about 20%-30%, which is relatively mild compared with the price reduction of chemical drugs.

　　Shi Lichen pointed out that for exclusive varieties, the incentive for manufacturers to reduce prices will not be particularly great. However, it is worth noting that the exclusive variety of proprietary Chinese medicines is a relative concept, which is mainly measured from the perspective of the number of manufacturers. If it is extended to the level of indications, many proprietary Chinese medicines generally do not have the so-called exclusive efficacy. Therefore, if the indications or functional indications are similar, the exclusive variety of proprietary Chinese medicines may not be exempted, and once it is included in the centralized purchase, it may face competition with other varieties with indications and functional indications, which will also bring pressure on enterprises to reduce prices.

　　Involving a number of A-share listed companies.

　　The reporter noted that at present, the collection of Chinese patent medicines led by Guangdong belongs to the stage of soliciting opinions, but if it falls, it may have an impact on the market structure of related drugs.

　　Among them, Qingkailing series drugs and Zishen Yutai Pill, the exclusive variety, are important products of Baiyun Mountain. Baiyun Mountain’s 2020 annual report shows that Qingkailing Granules achieved a revenue of 174 million yuan, with a gross profit margin of 53%, and the sales volume of Qingkailing series reached 461 million (bags/sticks/granules); The annual revenue of Zishen Yutai Pills was 342 million yuan, with a gross profit margin of 85.20%. The annual sales volume was 5.67 million boxes, of which 4.138 million boxes were purchased by medical institutions.

　　Xiangxue Pharmaceutical, another local listed company in Guangzhou, whose antiviral oral liquid and orange phlegm cough are also planned to be included in the list of centralized purchase. According to Xiangxue Pharmaceutical’s 2020 annual report, antiviral oral liquid and orange series brought 407 million yuan and 119 million yuan respectively, accounting for 17.12% of the company’s current revenue. These two kinds of drugs are mainly concentrated in pharmacies and other terminals.

　　Lianhua Qingwen is an important product of Yiling Pharmaceutical. According to the 2020 annual report of Yiling Pharmaceutical, its continuous flower clearing contributed 4.256 billion yuan in revenue, accounting for 48.46% of revenue, up 149.89% year-on-year. Yiling Pharmaceutical Co., Ltd. said that Lianhua Qingwen’s market share in retail terminal cold medicine/heat-clearing category reached 9.86% in 2020, and Lianhua Qingwen’s market share reached 37.9% in the sales revenue of proprietary Chinese medicines for cold medicine in China public medical market in the first half of 2020.

　　Tasly owns an exclusive variety of Compound Danshen Dripping Pills. Based on the company’s 2020 financial report, the total revenue of cardiovascular and cerebrovascular drugs including Compound Danshen Dripping Pills is 4.165 billion yuan (the data of Compound Danshen Dripping Pills is unknown). Last year, the drug was purchased by medical institutions for 107 million boxes. Buchang Pharmaceutical, the research and development company of Naoxintong Capsule, has a total revenue of 12.083 billion yuan for cardiovascular and cerebrovascular diseases (including Naoxintong Capsule) last year. The two packaging specifications of the drug are "36 capsules/box" and "48 capsules/box", and the annual purchase volume of the hospital is 41.22 million boxes and 56.84 million boxes respectively.

　　According to industry analysis, because the capital market is relatively unfamiliar with the collection of traditional Chinese medicine, the implementation of the policy may cause certain emotional impulses. In recent years, Chinese patent medicines have been suppressed by the policy, and the overall sales growth rate has continued to slow down. Due to the influence of auxiliary drug monitoring and medical insurance payment restrictions, the sales of some large varieties of Chinese traditional medicine injections have continued to decline. If the quantity procurement is introduced later, the Chinese patent medicine market will face greater uncertainty. There is a lack of data on the safety and effectiveness of proprietary Chinese medicines, and the product specifications are more complicated. At present, the country is expected to introduce proprietary Chinese medicines for re-evaluation after listing, and further standardize the proprietary Chinese medicine market. In the long run, it is expected that the introduction of centralized collection of proprietary Chinese medicines will benefit leading enterprises with high-quality resources, which is expected to further enhance the concentration of the industry.

　　News depth　　

　　How to avoid the upstream price increase making it difficult for the winning bidder to perform?

　　There should be more supporting policies for centralized collection of Chinese herbal medicines.

　　"The varieties of Chinese patent medicines that are planned to be collected this time involve 216 kinds of Chinese medicinal materials, of which 76 kinds of medicinal materials have increased by more than 10%, accounting for 35.19%, and the overall increase is 21.86%, which is higher than the average increase of market conditions in the past five years." Jia Haibin, founder of the big data platform of Tiandi Yuntu Chinese medicine industry, told the Yangcheng Evening News reporter that centralized collection of Chinese medicine is the only way for medical insurance to control fees and reduce drug prices, but the market background of continuous general increase in Chinese medicine prices should be included in the policy consideration, otherwise it is easy to happen that the winning bidder cannot fulfill the delivery due to the price increase of upstream Chinese medicine.

　　Jia Haibin pointed out that Chinese medicine is different from standard products such as chemical drugs and biological products, and the source of raw materials is the core of its quality control. At present, it is still difficult to fully implement the policy of centralized collection of traditional Chinese medicine, and it is highly probable that a small range and a small number of varieties will be tested to improve standards and processes and make up for policy loopholes. With the continuous implementation of centralized purchasing, on the one hand, major enterprises will continue to increase their efforts to enter the producing areas and strengthen the strategic reserve of core raw materials. On the other hand, the centralized procurement organization department will also tilt towards "the traceability of authentic medicinal materials" in terms of scoring standards and quality level division, which will play a positive role in accelerating the construction of traceability system of Chinese herbal medicines and improving the overall quality level of Chinese herbal medicines.

　　"It is suggested that the channels of appeal should be further opened." Shi Lichen suggested that in the centralized procurement of proprietary Chinese medicines, it should be suggested to establish a smoother communication mechanism, so that the selected enterprises can timely feedback the supply problems of raw materials in the performance of the procurement contract, and introduce more supporting policies to ensure the stable supply of drugs after winning the bid.

Guangxi news network-South China Morning PostNews (Reporter Zhong Liang) The 20-episode TV series "The Most Beautiful Time", which was jointly planned by Wuzhou Multi-department and Wenchuan Company, was filmed in Wuzhou and showed the new changes of Wuzhou’s local customs and rural revitalization. On March 14th, the launching ceremony and press conference were held. The play will be released in May this year, starring general directors Yi Li, Sun Jinliang and Yi Li, and many well-known actors.Union. The prototype of the main characters in the play originated from the typical characters emerging in the process of poverty alleviation and rural revitalization in Wuzhou City. The lens incorporates a lot of excellent local traditional culture, local customs and natural scenery, and shows the audience the local scenery and poverty alleviation industries such as Liubao tea, ice spring soybean milk, turtle paste, sugar orange and star anise, showing the great changes in rural areas of Wuzhou, Guangxi and China.

Photo courtesy of the organizer of "The Most Beautiful Time"